Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site
Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer (PCa). Current antiandrogen therapies induce resistant mutations at the hormone binding pocket (HBP) that convert the activity of these agents from antagonist to agonist. Thus, there is a high unmet me...
Main Authors: | Yangguang Liu, Meng Wu, Tianqi Wang, Yongli Xie, Xiangling Cui, Liujun He, Yang He, Xiaoyu Li, Mingliang Liu, Laixing Hu, Shan Cen, Jinming Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.01419/full |
Similar Items
-
Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance
by: Xiaohong eTian, et al.
Published: (2015-03-01) -
DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER
by: S. V. MISHUGIN, et al.
Published: (2016-12-01) -
Corrigendum: Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance
by: Xiaohong eTian, et al.
Published: (2015-05-01) -
Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study
by: Jin-Ge Zhao, et al.
Published: (2018-01-01) -
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
by: Meghan A. Rice, et al.
Published: (2019-08-01)